BridgeBio Oncology Therapeutics, Inc. announced positive preliminary safety and antitumor data across its three innovative RAS and PI3K programs.
The data includes promising efficacy results for BBO-8520 monotherapy in non-small cell lung cancer and encouraging responses in combination therapies.
This advancement positions BBOT to enable powerful dual-pathway targeting for patients with aggressive cancers.
BBO-8520 Monotherapy
Showed a 65% objective response rate in KRAS G12C NSCLC, with a potentially differentiated safety profile.
BBO-11818 Monotherapy
Demonstrated a partial response in pancreatic cancer with favorable safety profiles in dose escalation.
BBO-10203 Safety Profile
Showed no observed hyperglycemia events, initiating combination studies in CRC and BC.
- BBOT's portfolio advancements showcase a strong focus on precision oncology targeting RAS and PI3K pathways with a differentiated approach.
- The positive clinical data suggests potential for improved outcomes for patients with aggressive cancers through dual-pathway targeting.
The clinical data presented by BBOT highlights the promising efficacy and safety profiles of its RAS and PI3K programs, opening new avenues for combination therapies and patient treatment outcomes.